Table 2.
scFvs as cancer therapy.
| Target | Type of Cancer | Reference |
|---|---|---|
| scFv against tumor-cell surface antigen | ||
| scFv/Mesothelin | Epidermoid cervical carcinoma | [129] |
| Prostate-specific membrane antigen (PSMA) | Prostate cancer | [113] |
| Alpha-fetoprotein (AFP) | Hepatocellular carcinoma | [133] |
| CA125 | Breast cancer | [135] |
| Six-transmembrane epithelial antigen of the prostate (STEAP-1) | Prostate cancer | [130] |
| CD176 | Gastric and colorectal cancer | [134] |
| MG7-scFv/SEB | Gastric cancer | [136] |
| fAChR scFv/ETA | Rhabdomyosarcoma | [137] |
| CD22 | Lymphoma | [139] |
| Cholecystokinin-2/gastrin receptor (CCKR2) | Gastric adenocarcinoma | [97] |
| Epidermal growth factor receptor III (EGFRvIII) | Glioblastoma | [144,158] |
| CD123 | Erythroleukemia | [140] |
| scFv against tumor growth, survival, and proliferation | ||
| Frizzled class receptor 7 (Fzd7) | Breast cancer | [141] |
| Transferrin receptor 1 (TfR1) | Squamous cell carcinoma and hematopoietic neoplasms | [138,142,156,159] |
| p21Ras | Colorectal cancer | [146] |
| Cyclin D1 | Hepatocellular carcinoma | [148] |
| Cyclin E | Breast cancer | [149] |
| Integrin alphavbeta3 (ITG αvβ3) | Lung cancer | [150] |
| scFv against tumor migration | ||
| Reg4 | Gastric cancer | [151] |
| Insulin-like growth factor binding protein-2 (IGFBP2) | Glioblastoma | [152] |
| MUC18 | Breast cancer | [153] |
| Lidamidine apoprotein (LDP) | Hepatocellular carcinoma | [154] |
| scFv inducing tumor apoptosis | ||
| Epithelial cell adhesion molecule (EpCAM) | Triple-negative breast cancer (TNBC) | [155] |
| p53 | Solid tumors | [159,160] |